CVR 39103079Private limited company (ApS)Engroshandel med andre maskiner og andet udstyr (466400)HolteFounded 21 Nov 2017
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Pharma Components ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
-35.2K
DKK, annual report 2025
-371.6K on 2024
Result
-115.2K
DKK, annual report 2025
Equity
272.4K
DKK, annual report 2025
A.Rocket Holding ApSCVR 42268984, 100% of capital and votes
Anders Fossing Rielsince 28 Jun 2023
Owners of 5% or more. CVR registers shares in bands, not exact figures.
CVR 42268984100% of capital and votesnotified 28 Jun 2023since 14 Sep 2022
100% of capital and votes28 Jun 2023 to 28 Jun 2023
33.3% to under 50% of capital and votesnotified 22 Feb 202028 Aug 2019 to 22 Feb 2020
CVR 3745119350% to under 66.7% of capital and votesnotified 28 Jun 202321 Nov 2017 to 28 Jun 2023
CVR 4048278433.3% to under 50% of capital and votesnotified 22 Feb 202028 Aug 2019 to 22 Feb 2020
Ultimate controller
Holding in A.Rocket Holding ApS, since 27 Mar 2021
Holding company
CVR 42268984Private limited company (ApS)
Holding in Pharma Components ApS, since 14 Sep 2022
This company
Pharma Components ApS
CVR 39103079
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -35.2K, Operating profit -35.2K, Result for the year -115.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 619.3K, Equity 272.4K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -22 | 69 | 232 | 336 | -35 |
| Operating profit | -22 | +69 | +232 | +336 | -35 |
| Result for the year | -23 | +57 | +196 | +142 | -115 |
| Equity | -8 | 49 | 246 | 388 | 272 |
| Total assets | 59 | 127 | 627 | 805 | 619 |
| Employees (average) | 0 | 0 | 0 | 0 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | n.m.note 1 | n.m.note 1 | 238.8% | 44.9% | -110.5% |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Pharma Components ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseBonus issue from reserves | None | None | None | 40,000 | |
| FoundingCashPaid in 100 | None | 100 | None | 100 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
4 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Ny adresse: c/o Anders Fossing Riel, Arnegårds Alle 12, Søllerød, 2840 Holte
Ny adresse: c/o Anders Fossing Riel, Lyngbakkevej 18A, Søllerød, 2840 Holte
Bestyrelse:
Tiltrådte:
Anders Fossing Riel, (formand), den 28.06.2023.
Direktion:
Fratrådte:
Patrick Lund Ossian, (adm. dir), den 28.06.2023.
Tiltrådte:
Anders Fossing Riel, (adm. dir), den 28.06.2023.
Virksomheden er omregistreret fra Iværksætterselskab til Anpartsselskab
Vedtægter ændret: 13.11.2020
Nyt navn: Pharma Components ApS
Kapitalforhøjelsen er besluttet den 13.11.2020.
kr. 39.900,00, indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 40.000,00.
Stiftelsesdato: 21.11.2017.
Virkningsdato: 21.11.2017.
Seneste vedtægtsdato: 21.11.2017.
Kapital:
kr. 100,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 100,00 til kurs 100,00, fuldt indbetalt.
Stifter:
CVR-NR. 37451193 Ossian IVS, Viggo Jarls Vej 23, Søllerød, 2830 Virum, den 21.11.2017.
Direktion:
Patrick Lund Ossian (adm. dir), den 21.11.2017.
Virksomheden tegnes af en direktør alene.
Første regnskabsår:
21.11.2017 - 31.12.2018.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med komponenter til fødevare og medicinal industrien og hermed forbundet virksomhed.
P-number 1023047787Arnegårds Alle 12, 2840 Holte